Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep 16:8:18.
doi: 10.1186/1478-7547-8-18.

Within a smoking-cessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness?

Louisa G Gordon  1 , Nicholas G Hirst, Robert P Young, Paul M Brown
Affiliations

Within a smoking-cessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness?

Louisa G Gordon et al. Cost Eff Resour Alloc. .

Abstract

Background: Many smoking-cessation programs and pharmaceutical aids demonstrate substantial health gains for a relatively low allocation of resources. Genetic information represents a type of individualized or personal feedback regarding the risk of developing lung cancer, and hence the potential benefits from stopping smoking, may motivate the person to remain smoke-free. The purpose of this study was to explore what the impact of a genetic test needs to have within a typical smoking-cessation program aimed at heavy smokers in order to be cost-effective.

Methods: Two strategies were modelled for a hypothetical cohort of heavy smokers aged 50 years; individuals either received or did not receive a genetic test within the course of a usual smoking-cessation intervention comprising nicotine replacement therapy (NRT) and counselling. A Markov model was constructed using evidence from published randomized controlled trials and meta-analyses for estimates on 12-month quit rates and long-term relapse rates. Epidemiological data were used for estimates on lung cancer risk stratified by time since quitting and smoking patterns. Extensive sensitivity analyses were used to explore parameter uncertainty.

Results: The discounted incremental cost per QALY was AU$34,687 (95% CI $12,483, $87,734) over 35 years. At a willingness-to-pay of AU$20,000 per QALY gained, the genetic testing strategy needs to produce a 12-month quit rate of at least 12.4% or a relapse rate 12% lower than NRT and counselling alone for it to be equally cost-effective. The likelihood that adding a genetic test to the usual smoking-cessation intervention is cost-effective was 20.6% however cost-effectiveness ratios were favourable in certain situations (e.g., applied to men only, a 60 year old cohort).

Conclusions: The findings were sensitive to small changes in critical variables such as the 12-month quit rates and relapse rates. As such, the cost-effectiveness of the genetic testing smoking cessation program is uncertain. Further clinical research on smoking-cessation quit and relapse rates following genetic testing is needed to inform its cost-effectiveness.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Illustration of Markov Model.
Figure 2
Figure 2
Scatterplot of incremental cost per QALY gained with 95% ellipse and willingness-to-pay (WTP) AU$20,000 per QALY gained.
See this image and copyright information in PMC

References

    1. Scollo MM, Winstanley MH, (Eds) Tobacco in Australia: Facts and Issues. Third. Melbourne: Cancer Counci Victoria; 2008.
    1. World Health Organisation Regional Office for Europe. Prevalence of daily smoking by country, adults aged 15 years and over, European Region. WHO; 2005.
    1. Warner KE, Mackay JL. Smoking cessation treatment in a public-health context. Lancet. 2008;371:1976–1978. doi: 10.1016/S0140-6736(08)60846-6. - DOI - PubMed
    1. Cromwell J, Bartosch WJ, Fiore MC, Baker T, Hasselblad V. Cost effectiveness of the AHCPR guidelines for smoking. Journal of the American Medical Association. 1997;278:1759–1766. doi: 10.1001/jama.278.21.1759. - DOI - PubMed
    1. Gordon LG, Graves N, Hawkes A, Eakin E. A review of the cost-effectiveness of face-to-face behavioural interventions for smoking, physical activity, diet and alcohol. Chronic Illness. 2007;3:101–129. doi: 10.1177/1742395307081732. - DOI - PubMed